Vitrafy Life Sciences (VFY) H2 2025 earnings summary

Executive summary

• Leadership transition: Kate Munnings retires as CEO, remains as Non-Executive Director; Brent Owens appointed as new CEO, effective September 2025, ensuring continuity and strategic focus.

• Delivered on IPO commitments, including successful ASX listing in November 2024, raising AUD 35 million in primary capital and securing a AUD 4.8 million Industry Growth Program grant.

• Expansion in animal reproduction, U.S. operations established, and strong progress in commercialization, market development, and technology validation in cell & gene therapy, aquaculture, and bovine applications.

• Completed Phase 1 blood platelets study with U.S. Military, exceeding industry standards and progressing to Phase 2.

• Commercialisation pipeline advancing with staged partner engagement and product launches planned for FY26.

Financial highlights

• FY25 sales revenue increased 75% year-over-year, driven by aquaculture pilot and Huon growth; total income for FY25 was $2.8m, up from $2.1m in FY24.

• AUD 2.4 million in grant cash received, with further revenue expected as expenses are matched.

• Significant one-off, non-cash costs of $18.9m from convertible note conversion at IPO impacted reported loss; normalised loss before income tax for FY25 was $(11.3)m after removing non-recurring items.

• R&D Tax Incentive income declining as focus shifts to commercialization; R&D spend expected to increase by 50% year-over-year, peaking in the first half of FY 2026.

• Operating cash outflow of AUD 8.8 million for the year; cash and liquid assets of AUD 29.6 million at year-end, providing runway into at least calendar year 2027.

Outlook and guidance

• Focused on accelerating commercialization, securing new revenue-generating contracts, and capturing market share, especially in animal and blood component markets.

• Product launches for VCU2 and LifeChain on track and on budget, with first releases expected in the first half of the financial year; unregulated product launch planned for H1 FY26, regulated medical device launch in H2 FY26.

• Aggressive scaling and build-out of U.S. operations and supply chain to support market entry and customer delivery.

• Phase 2 blood platelets study to be completed and commercialisation advanced.